Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468833 | 0.86 | AKR1B1 (0.47) | ALDH1A1GAAHSD17B10AKR1B1CYP1A2 | |
| SCHEMBL12984975 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAHSD17B10GRM2GRM3 | |
| SCHEMBL48506 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAHSD17B10GRM2GRM3 | |
| SCHEMBL167735 | 0.84 | PSIP1 (0.52) | ALDH1A1GAAHSD17B10AKR1B1CYP1A2 | |
| SCHEMBL8930343 | 0.84 | AKR1B1 (0.52) | ALDH1A1GAAHSD17B10AKR1B1CYP1A2 | |
| SCHEMBL13667982 | 0.83 | KEAP1 (0.53) | ALDH1A1GAAHSD17B10GRM2GRM3 | |
| SCHEMBL4137892 | 0.82 | AKR1B1 (0.50) | ALDH1A1GAAHSD17B10AKR1B1CYP1A2 | |
| SCHEMBL14033126 | 0.82 | HTR6 (0.60) | GAAAKR1B1CYP1A2CYP2C19PTGDR2 | |
| SCHEMBL4026429 | 0.82 | CA1 (0.55) | GAAHSD17B10AKR1B1CYP1A2CYP2C19 | |
| SCHEMBL353553 | 0.81 | GLS (0.52) | ALDH1A1GAAHSD17B10GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-18 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116490499-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116023375-A | Heterocyclic derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20220306630-A1 | AGONISTS OF ROR GAMMAt | BRISTOL MYERS SQUIBB CO (US) | 2022-09-29 | — | — | US | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1660467-A2 | AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2006001751-A1 | CHEMICAL COMPOUNDS I | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558607-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-24 | — | — | US | disclosed |
| WO-2004041813-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148640-A1 | Aminofurazan compounds useful as protein kinase inhibitors | PHKG1, MAP3K20, MAP3K5 | ALDH1A1 2638/4885GAA 554/4885HSD17B10 2615/4885 |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | ALDH1A1 4771/4885GAA 1294/4885HSD17B10 3750/4885 |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | ALDH1A1 4413/4885GAA 1724/4885HSD17B10 3755/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | ALDH1A1 4067/4885GAA 3261/4885HSD17B10 3996/4885 |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | CSNK1A1, CSNK1G1, CSNK1E | ALDH1A1 2154/4885GAA 1002/4885HSD17B10 2077/4885 |
| US-20220306630-A1 | AGONISTS OF ROR GAMMAt | RORB, RORA, RORC | ALDH1A1 331/4885GAA 1245/4885HSD17B10 539/4885 |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | CSNK1A1, CSNK1G1, CSNK1E | ALDH1A1 2154/4885GAA 1002/4885HSD17B10 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.